Arthur Lieberman
Plus aucun poste en cours
Profil
Arthur Lieberman has been a Director of TyRx Pharma, Inc. since 1998.
He is a Partner and Founder of Lieberman & Nowak.
Prior to founding Lieberman & Nowak, Mr. Lieberman was a Partner of Hopgood, Calimafde, Kalil, Blaustein & Lieberman.
He was a Director of University Patents, Inc. Mr. Lieberman has 30 years of patent licensing and litigation experience in the chemical and polymer industries.
He received a Bachelor's degree in Electrical Engineering from Cornell University and New York University and a JD from the Brooklyn Law School.
Anciens postes connus de Arthur Lieberman
| Sociétés | Poste | Fin |
|---|---|---|
TYRX, Inc.
 TYRX, Inc. Electronic Equipment/InstrumentsElectronic Technology TYRX, Inc. designs and manufactures medical-pharmaceutical combination devices. The firm commercializes implantable combination drug and device products focused on infection control including the AIGISRx Antibacterial Envelope, designed to reduce surgical site infections associated with cardiac implantable electronic devices (CIEDs). Its AIGISRx products contain the antimicrobial agents, rifampin and minocycline, which have been shown to reduce infection by pathogens responsible for the majority of CIED infections, including superbugs such as methicillin-resistant S. aureus (MRSA). The company was founded in 1998 by Satish Pulapura and Arikha Moses and is headquartered in Monmouth Junction, NJ. | Directeur/Membre du Conseil | - |
Formation de Arthur Lieberman
| Cornell University | Undergraduate Degree |
| Brooklyn Law School | Graduate Degree |
Expériences
Fonctions occupées
Sociétés liées
| Entreprise privées | 1 |
|---|---|
TYRX, Inc.
TYRX, Inc. Electronic Equipment/InstrumentsElectronic Technology TYRX, Inc. designs and manufactures medical-pharmaceutical combination devices. The firm commercializes implantable combination drug and device products focused on infection control including the AIGISRx Antibacterial Envelope, designed to reduce surgical site infections associated with cardiac implantable electronic devices (CIEDs). Its AIGISRx products contain the antimicrobial agents, rifampin and minocycline, which have been shown to reduce infection by pathogens responsible for the majority of CIED infections, including superbugs such as methicillin-resistant S. aureus (MRSA). The company was founded in 1998 by Satish Pulapura and Arikha Moses and is headquartered in Monmouth Junction, NJ. | Electronic Technology |
